Trial Profile
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY TO COMPARE THE EFFECT OF 52 WEEKS TREATMENT WITH LAF237 50 MG BID TO METFORMIN UP TO 1000 MG BID IN DRUG NAIVE PATIENTS WITH TYPE 2 DIABETES
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jan 2015
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 04 May 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00099866).
- 05 Nov 2010 New trial record.